Portal de Periódicos da CAPES

Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma

2021; Elsevier BV; Volume: 6; Issue: 4 Linguagem: Inglês

10.1182/bloodadvances.2021005385

2473-9537

Timothy Voorhees, Beibo Zhao, Jorge D. Oldan, George Hucks, Amir H. Khandani, Christopher Dittus, Jennifer K. Smith, J. Kaitlin Morrison, Catherine Cheng, Anastasia Ivanova, Steven Park, Thomas C. Shea, Anne Beaven, Gianpietro Dotti, Jonathan S. Serody, Barbara Savoldo, Natalie S. Grover,

Cancer Immunotherapy and Biomarkers

Our group has recently demonstrated that chimeric antigen receptor T-cell therapy targeting the CD30 antigen (CD30.CAR-T) is highly effective in patients with relapsed and refractory (r/r) classical Hodgkin lymphoma (cHL). Despite high rates of clinical response, relapses and progression were observed in a subset of patients. The objective of this study was to characterize clinical and correlative factors associated with progression-free survival (PFS) after CD30.CAR-T cell therapy. We evaluated correlatives in 27 patients with r/r cHL treated with lymphodepletion and CD30.CAR-T cells. With a median follow-up of 9.5 months, 17 patients (63%) progressed, with a median PFS of 352 days (95% confidence interval: 116-not reached), and 2 patients died (7%) with a median overall survival of not reached. High metabolic tumor volume (MTV, >60 mL) immediately before lymphodepletion and CD30.CAR-T cell infusion was associated with inferior PFS (log rank, P = .02), which persisted after adjusting for lymphodepletion and CAR-T dose (log rank, P = .01 and P = .006, respectively). In contrast, receiving bridging therapy, response to bridging therapy, CD30.CAR-T expansion/persistence, and percentage of CD3+PD-1+ lymphocytes over the first 6 weeks of therapy were not associated with differences in PFS. In summary, this study reports an association between high baseline MTV immediately before lymphodepletion and CD30.CAR-T cell infusion and worse PFS in patients with r/r cHL. This trial was registered at www.clinicaltrials.gov as #NCT02690545.